FARN Faron Pharmaceuticals Oy

0.3621USD27.50 GBp · LSE-1.79%Mkt Cap: 73.47M USDP/E: —

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidate is Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of…

Key Statistics

Company
Market Cap73.47M USD
Enterprise Value56.29M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-29.90M USD
Revenue/Share0.01 USD
Last Price0.3621 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees36
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINFI4000153309
Valuation
P/E (Trailing)—
P/E (Forward)-3.64
PEG—
EV/EBITDA-2.22
EV/Revenue—
P/S—
P/B5.75
EPS (TTM)-0.11 USD
EPS (Forward)-0.08 USD
52W Range
0.32921% of range2.634
52W High2.634 USD
52W Low0.3292 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE147.28%
ROA-158.73%
ROIC—
ROCE—
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-19.65M USD
CapEx (TTM)243.49K USD
FCF Margin—
FCF Yield-18.22%
Net Debt-15.42M USD
Net Debt/EBITDA0.73
Net Debt/FCF—
Balance Sheet
Debt/Equity-1.33
Current Ratio2.40
Quick Ratio2.28
Book Value/Sh0.05 USD
Cash/Share0.17 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)12.87 USD
Upside (mean)+3452.7%
Target Range12.87 USD – 12.87 USD
# Analysts1
Ownership
Shares Out.202.88M
Float136.59M
Insiders15.89%
Institutions20.68%
Technical
SMA 500.4476 (-19.1%)
SMA 2000.5477 (-33.9%)
Beta1.13
S&P 52W Chg12.08%
Avg Vol (30d)43.17K
Avg Vol (10d)68.20K
Technical Indicators
RSI (14)22.5
MACD-1.7220
MACD Signal-1.6266
MACD Hist.-0.0954
BB Upper0.4370 USD
BB Middle0.3974 USD
BB Lower0.3577 USD
BB Width19.97%
ATR (14)0.0401 USD
Vol Ratio (20d)3.53x

About Faron Pharmaceuticals (LON: FARN)

›

Faron Pharmaceuticals (LON: FARN) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 36 employees.

The shares were at 27.50 GBp on 19 November 2026, down 85.5% over 52 weeks. Its 52-week range is 25.00 GBp to 200.00 GBp: the price is 86.3% below the high and 10.0% above the low.

Its market capitalisation is 55.79M GBP.

Faron Pharmaceuticals reports return on equity of 147.3% and an operating margin of 0.0%.

It holds more cash than debt, a net cash position of 14.06M EUR. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 4 March 2027.